NY-FIRST-EAGLE-INV-MGMT
3.8.2020 12:02:05 CEST | Business Wire | Press release
First Eagle Investment Management, LLC (“First Eagle”) is pleased to announce plans to open a branch of First Eagle Investment Management Ltd. in Munich, Germany, through which the firm will serve international wholesale clients in Europe, the Middle East and Africa (EMEA) as well as in other non-US domiciles. The Munich office will be overseen by Matthieu Louanges, who joins First Eagle on August 3 as head of its international wholesale business. Louanges will be stationed in Munich in preparation for the official opening of First Eagle’s office there, expected in late 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200803005114/en/
“First Eagle traces its origin to Germany, and we are excited to reestablish our local presence there after an absence of more than 80 years,” said Mehdi Mahmud, President and Chief Executive Officer of First Eagle. “Arnhold and S. Bleichroeder, the predecessor firm to First Eagle, represented the amalgamation of two storied German banks: Berlin-based S. Bleichroeder, founded in 1803, and Dresden-based Gebr. Arnhold, founded in 1864. First Eagle’s European roots run deep, and the plan to open an office in continental Europe feels like something of a homecoming. Under the leadership of Matthieu, who has extensive experience working with international clients and building and managing multinational franchises, our Munich location will help us strengthen our partnership with Amundi Asset Management and enhance our client service outreach for non-US clients worldwide.”
Louanges and his team, located in Munich and New York, will be responsible for First Eagle’s international wholesale distribution business, which includes the firm’s distribution partnership with Amundi Asset Management. The European Union and the European continent will continue to be key elements of First Eagle’s international business, and the firm expects Asia and South America to be particularly important regions of business growth moving forward. Highlighting the firm’s commitment to its international business, Louanges will report to Mahmud and will join First Eagle’s Management Committee, marking the first time a Management Committee member has been based outside of the US.
French/German binational Louanges joins First Eagle after more than 20 years at PIMCO, where he was one of the most senior leaders in PIMCO’s EMEA franchise; as Managing Director, he most recently headed up the firm’s global relationship with Allianz. Earlier in his PIMCO tenure, Louanges launched the company’s EMEA insurance channel, which over time evolved into the broader financial institutions group, and he had broad oversight responsibility for PIMCO’s business in Switzerland and France as well as its EMEA client solutions team. Louanges joined PIMCO as a portfolio manager of mutual funds and institutional mandates in 2000 upon its acquisition by Allianz, where he had been playing a similar role.
“I am excited to join First Eagle Investment Management and become a member of its Management Committee,” said Louanges. “While First Eagle’s investment proposition already has a broad client base globally, given the increasingly uncertain economic and market environment, there remains a strong appetite for solutions that combine the potential for attractive returns with downside protection over full market cycles. I look forward to working closely with Mehdi and the rest of my new colleagues to make First Eagle’s time-tested, differentiated investments solutions accessible to international clients and to support our important partnership with Amundi Asset Management.”
Louanges succeeds Robert H. Hackney, Jr., a 25-year veteran of First Eagle. Hackney will remain with the firm, first to assist in the transition of his leadership of the international wholesale distribution business to Louanges and afterward as an advisor to Mahmud and the firm’s leadership team on strategic initiatives. “Robert’s leadership has been integral to the success of our partnership with Amundi Asset Management and our international wholesale business. We have benefited from his keen strategic perspective over the years, and I look forward to his ongoing counsel as we continue to evolve the firm,” said Mahmud.
ABOUT FIRST EAGLE INVESTMENT MANAGEMENT
First Eagle Investment Management is an independent, privately owned investment management firm headquartered in New York with approximately $101 billion in assets under management as of June 30, 2020. Dedicated to providing prudent stewardship of client assets, the firm focuses on active, fundamental and benchmark-agnostic investing, with a strong emphasis on downside protection. Over a long history dating back to 1864, First Eagle has helped its clients avoid permanent impairment of capital and earn attractive returns through widely varied economic cycles—a tradition that is central to its mission today. The firm’s investment capabilities include equity, fixed income, alternative credit and multi-asset strategies. For more information on First Eagle, please visit www.feim.com . For information on First Eagle Alternative Credit, please visit www.feac.com .
First Eagle Investment Management is the brand name for First Eagle Investment Management, LLC and its subsidiary investment advisers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200803005114/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
